Stephen has been in biopharma for over 25 years and has worked in neurology with Elan Pharmaceuticals, gene therapy for rare diseases with Audentes Therapeutics and Encoded Therapeutics, virology with Gilead Sciences, and oncology with Genentech, Medivation, Clovis Oncology, and 23andme, and, currently, Corcept Therapeutics. I started my career in clinical operations where I led company-sponsored studies and oversaw investigator-initiated studies. I made the move to project/program management in 2014 to work on all phases of drug development from discovery through post-marketing activities and have assumed business development and alliance management responsibilities as needed for my programs. I earned an MBA through the Gilead Sciences MBA cohort program, an MA in East Asian Art from the Sotheby’s Institute of Art in London, and an MS in Project Management. I am a team leader dedicated to bringing new drugs to patients. I believe in life long learning, appreciate the here and now, strive to treat everyone with compassion and dignity, and lead with integrity and drive to meet corporate goals.
